OncoMatch/Clinical Trials/NCT06445803
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Is NCT06445803 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） for acute lymphoblastic leukemia, in relapse.
Treatment: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） — This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20-targeted therapy — B-NHL, second or greater relapse
Second or greater relapse (CD20 regimens must be included)
Must have received: tyrosine kinase inhibitor — Ph+ ALL
Ph+ ALL intolerance to TKI or refractory or relapse after treatment with at least two and more TKIs
Cannot have received: (bendamustine, fludarabine)
Prior treatment with bendamustine-containing or fludarabine
Cannot have received: anti-T-cell monoclonal antibody
Exception: within 8 weeks
Anti-T-cell monoclonal antibody, donor lymphocyte infusion, and CNS radiotherapy within 8 weeks
Cannot have received: (lenalidomide, bortezomib)
Exception: within 2 weeks
Chemotherapy, lenalidomide, bortezomib within 2 weeks
Cannot have received: (vincristine)
Exception: within 1 week
vincristine within 1 week
Cannot have received: glucocorticoid (prednisone)
Exception: prednisone ≥7.5 mg/d or equivalent within 72 h
glucocorticoids (prednisone ≥7.5 mg/d or equivalent) within 72 h
Lab requirements
Blood counts
Main tissues and organs function well
Kidney function
Main tissues and organs function well
Liver function
Main tissues and organs function well
Cardiac function
Main tissues and organs function well
Main tissues and organs function well
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify